The Filing Desk

Agios Pharmaceuticals vs Aytu Biopharma

Agios Pharmaceuticals AGIO · Aytu Biopharma AYTU · Pharmaceuticals

Aytu Biopharma reported revenue of $58 million in fiscal 2026, about the same as Agios Pharmaceuticals' $54 million in fiscal 2025. Agios Pharmaceuticals' revenue grew 48.0% in its latest year, and Aytu Biopharma's fell 13.3%. Agios Pharmaceuticals had an operating margin of -873.9%, against -14.4% at Aytu Biopharma. Free cash flow was −$377 million at Agios Pharmaceuticals and $3 million at Aytu Biopharma. Their fiscal years end in different months (December 31 and June 30), so the periods don't line up exactly.

Side by side

Agios PharmaceuticalsAytu Biopharma
Latest fiscal yearFY2025, Dec 31, 2025FY2026, Jun 30, 2026
Revenue$54M$58M
Revenue growth48.0%−13.3%
Revenue growth a year, last 5 years—−2.6%
Gross margin88.3%64.0%
Operating margin−873.9%−14.4%
Net margin−764.0%−24.8%
Free cash flow−$377M$3M
Free cash flow margin−698.3%5.7%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count0.1%96.2%
Last close$28.76$2.66
P/E at the last close——
Insider trades, last 12 monthssold $4.3 million—
Piotroski F-score——
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Agios PharmaceuticalsAytu Biopharma
Operating margin
Percent of revenue
Agios PharmaceuticalsAytu Biopharma
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Agios PharmaceuticalsAytu Biopharma

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Agios Pharmaceuticals and Aytu Biopharma pages.